This article is more than 5 years old. Information may no longer be current.

Trabeculectomy with MMC lowered IOP in patients with secondary glaucoma from Behçet's disease

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Most eyes treated with trabeculectomy with mitomycin-C for secondary glaucoma from Behçet's disease achieved an IOP of 20 mm Hg or below at 1 year postop, a study found.

Ufuk Elgin, MD, and colleagues reviewed outcomes of 23 eyes of 13 patients that underwent the procedure. Their results are published in the January issue of the Journal of Glaucoma.

At baseline, mean IOP was 30.9 mm Hg with a mean 3.3 glaucoma medications. By 6 months postop, mean IOP had dropped to 16.8 mm Hg with a mean 1.7 medications. At 1 year follow-up, mean IOP was 18.5 mm Hg with a mean 2.6 glaucoma medications.

At 1 year, 82.6% of eyes had achieved an IOP of 20 mm Hg or below, which was the study's definition of success.